Repligen Co. (NASDAQ:RGEN) Receives $190.25 Average Target Price from Analysts

Repligen Co. (NASDAQ:RGENGet Free Report) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $190.25.

A number of research analysts have recently weighed in on RGEN shares. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday.

Check Out Our Latest Research Report on Repligen

Repligen Trading Up 2.4 %

Shares of NASDAQ:RGEN opened at $146.06 on Friday. The business’s 50-day moving average is $140.26 and its 200 day moving average is $143.12. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The firm has a market capitalization of $8.18 billion, a P/E ratio of -394.59, a P/E/G ratio of 4.29 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGENGet Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the company posted $0.23 EPS. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, research analysts predict that Repligen will post 1.52 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently modified their holdings of the company. O Shaughnessy Asset Management LLC lifted its position in shares of Repligen by 6.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 125 shares in the last quarter. UniSuper Management Pty Ltd lifted its position in shares of Repligen by 100.0% during the first quarter. UniSuper Management Pty Ltd now owns 800 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 400 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Repligen by 1.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 38,559 shares of the biotechnology company’s stock worth $7,086,000 after purchasing an additional 567 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Repligen by 21.6% during the first quarter. Advisors Asset Management Inc. now owns 13,827 shares of the biotechnology company’s stock worth $2,543,000 after purchasing an additional 2,456 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

(Get Free Report

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.